Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Overview of attention for article published in Allergy, Asthma & Clinical Immunology, January 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 9,074 followers.

RT @MacDeptMed: PUBLICATION OF THE WEEK: Targeting the IL-5 Pathway in Eosinophilic #Asthma: A Comparison of Mepolizumab to Benralizumab in…

PUBLICATION OF THE WEEK: Targeting the IL-5 Pathway in Eosinophilic #Asthma: A Comparison of Mepolizumab to Benralizumab in the Reduction of Peripheral Eosinophil Counts https://t.co/bbfpLGoxLV #ArianGhassemian, #JaneJiyoonPark, #MichaelTsoulis & #Haro

RT @ImmunAllergyBMC: Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of per…

RT @ImmunAllergyBMC: Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of per…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.